Untitled
1. Conceptual Origins of Artificial Circulation
The theoretical premise of mechanical circulatory support preceded practical clinical execution by more than a century:
César Julien Jean Le Gallois (1812): Formulated the foundational postulate of extracorporeal circulation in Expériences sur le principe de la vie, stating that if an artificial injection of arterialized blood could be continuously supplied to any organ or body segment, life in that part could be maintained indefinitely.
Charles-Édouard Brown-Séquard (1848–1858): Conducted blood aeration experiments using animal corpses and amputated limbs, injecting defibrinated, oxygenated blood and demonstrating restoration of muscular irritability and reflex activity.
Max von Frey and Max Gruber (1885): Constructed the first prototype of an artificial heart-lung apparatus at the University of Leipzig. Their device passed blood in a thin film across the inner surface of an inclined rotating cylinder filled with oxygen, anticipating the film oxygenator.
Carl Jacobj (1890): Developed an apparatus utilizing excised donor lungs from an animal as the oxygenation mechanism to perfuse isolated organs, establishing early physiological perfusion platforms.
2. Anticoagulation and Reversal Pharmacology
Clinical extracorporeal perfusion remained unviable until blood could travel over synthetic surfaces without fatal thrombogenesis:
Heparin Discovery (1916): Jay McLean, a second-year medical student at Johns Hopkins University working under physiologist William Henry Howell, isolated a fat-soluble anticoagulant from canine liver tissue while investigating thromboplastic substances. Howell named it heparin (from the Greek hepar, liver) in 1918.
Purification for Human Use (1933–1937): Early heparin extracts were toxic and caused pyrogenic reactions. Charles Best, Arthur Charles, and David Scott at the Connaught Laboratories (University of Toronto) purified bovine heparin, establishing its potency in units. In 1937, Canadian surgeon Gordon Murray initiated the first successful clinical human trials using intravenous heparin for vascular surgery and thrombosis prevention.
Protamine Neutralization (1937–1939): Erwin Chargaff and Kenneth B. Olson discovered that protamine (a basic polycationic peptide derived from salmon sperm) rapidly binds acidic, negatively charged heparin molecules via electrostatic interaction to form a stable, inactive salt precipitate, providing the specific reversal agent vital for decannulation.
3. Development of Perfusion Hardware
3.1 The Blood Pump
Roller Pump (1855–1934):
In 1855, Porter and Bradley patented the basic continuous rotary peristaltic mechanism, later modified by Eugene E. Allen in 1887.
In 1934, American surgeon Michael E. DeBakey adapted this roller-type peristaltic pump for blood transfusions to minimize erythrocyte trauma. John Heysham Gibbon Jr. incorporated the DeBakey roller pump into his experimental cardiopulmonary bypass circuits.
Centrifugal Pump (1970s):
Developed by Eugene Bernstein and Delaria (commercialized as the Bio-Medicus pump by Medtronic), the vortex-based, constrained-vortex centrifugal pump reduced blood-gas interface trauma, cavitation risks, and catastrophic line overpressurization compared to positive-displacement roller pumps.
3.2 Evolution of the Oxygenator
Film and Screen Oxygenators (1930s–1950s):
John H. Gibbon Jr. and Mary Hopkinson Gibbon (his wife and research partner), alongside IBM engineers led by Thomas J. Watson, engineered vertical wire-mesh screen oxygenators where deoxygenated blood descended in a thin film over stationary screens within an oxygen chamber.
Viking Olov Björk (1948) and later Frederick S. Cross and Earl B. Kay (1956) refined the rotating disc oxygenator (Kay-Cross oxygenator), which spun multiple parallel stainless-steel discs through a blood reservoir inside an oxygen-rich atmosphere.
Bubble Oxygenators (1950s):
In 1950, Leland C. Clark Jr. and Frank Gollan developed direct gas-dispersion bubbling methods and introduced polydimethylsiloxane (Antifoam A) to safely collapse blood foam.
In 1955, at the University of Minnesota, Richard DeWall (perfusionist/surgical fellow) and C. Walton Lillehei engineered the DeWall-Lillehei bubble oxygenator using inexpensive polyvinyl chloride (PVC) tubing: a vertical mixing column for bubbling oxygen through venous blood, an inclined debubbling chamber coated with Antifoam A, and a helical settling reservoir.
Membrane Oxygenators (1955–Present):
Willem J. Kolff and Robert Balzer (1955) applied polyethylene membranes to gas exchange. George H. A. Clowes Jr. (1956) developed the first clinical flat-plate membrane oxygenator, eliminating direct blood-gas contact to reduce hemolysis and protein denaturation.
Hollow-Fiber Technology: During the late 1970s and 1980s, microporous polypropylene hollow fibers were introduced, succeeded in the 2000s by non-porous poly-4-methyl-1-pentene (PMP) diffusion membranes, minimizing plasma leakage during prolonged ECMO and CPB.
4. Milestone Human Clinical Trials
4.1 Clarence Dennis and the First Clinical CPB Attempt (1951)
Date: April 5, 1951
Institution: University of Minnesota Hospitals
Surgeon: Dr. Clarence Dennis
Patient: Jacqueline Smith, a 6-year-old girl with an ostium primum atrial septal defect (ASD) and complex endocardial cushion defect.
Equipment: Modified rotating-screen oxygenator and iron-finger pumps.
Outcome: Dennis achieved full bypass, but the patient died intraoperatively from uncontrollable hemorrhage and heart failure related to an unexpected, uncorrectable anatomical malformation (common atrioventricular canal). This was the first human application of an extracorporeal circuit for open-heart surgery.
4.2 John Gibbon’s Triumphant First Successful Repair (1953)
Date: May 6, 1953
Institution: Thomas Jefferson University Hospital, Philadelphia
Surgeon: Dr. John Heysham Gibbon Jr.
Perfusionist/Co-investigator: Mary Gibbon
Patient: Cecelia Bavolek, an 18-year-old female with a massive secundum ASD.
Run Details: The patient was supported on the IBM-Gibbon Model II vertical-screen heart-lung machine for of total cardiopulmonary bypass (pump run time: ). The defect was closed successfully, and Bavolek made a complete recovery.
Aftermath: Following the deaths of his next four clinical patients, Gibbon ceased cardiac surgery, leaving future developments to other centers.
4.3 C. Walton Lillehei and Controlled Cross-Circulation (1954–1955)
Date: March 26, 1954
Institution: University of Minnesota
Surgeon: Dr. C. Walton Lillehei, assisted by Morley Cohen, Herbert Warden, and Richard Varco
Concept: A compatible human donor (typically a parent) acted as the oxygenator and blood reservoir for the pediatric patient. Low-flow perfusion was guided by the "azygos flow principle" established by Morley Cohen and Herbert Warden (demonstrating that survival required only , approximately of normal resting cardiac output).
First Patient: Gregory Glidden, a 13-month-old infant with a ventricular septal defect (VSD), cross-circulated with his father. The defect was repaired, but the infant died on postoperative day 11 of severe bilateral pneumonia.
Clinical Run: Lillehei successfully treated 45 critically ill children using cross-circulation over 14 months, repairing VSDs, tetralogy of Fallot, and atrioventricular canal defects before shifting entirely to the DeWall-Lillehei bubble oxygenator in 1955.
5. Myocardial Protection and Hypothermia
Chronology of Myocardial Preservation Techniques:
1950 (Bigelow) --> Systemic Hypothermia concept in dogs
1952 (Lewis) --> Surface hypothermia human ASD closure (Jacqueline Johnson)
1955 (Melrose) --> Potassium citrate chemical arrest (Melrose solution)
1970s (Hearse) --> St. Thomas' Hospital crystalloid cardioplegia
1970s (Buckberg)--> Cold blood cardioplegia with substrate enhancement
1990s (del Nido)--> Single-dose lidocaine-based depolarizing crystalloid
5.1 Systemic and Topical Hypothermia
Wilfred G. Bigelow (1950): Demonstrated at the University of Toronto that induced systemic hypothermia reduced oxygen consumption ( temperature coefficient effect), extending safe circulatory arrest time in animal models.
F. John Lewis and Mansur Taufic (September 2, 1952): Performed the world's first successful open-heart operation using systemic surface cooling (immersion in refrigerated blankets) without CPB on Jacqueline Johnson (a 5-year-old girl with an ASD) at the University of Minnesota. Total circulatory arrest time was at .
Norman Shumway (1959): Introduced local, topical myocardial cooling using iced isotonic saline slush into the pericardium to preserve ischemic myocardium during aortic cross-clamping.
5.2 Chemical Cardioplegia
Melrose Formulation (1955):
Denis Melrose and colleagues at the Postgraduate Medical School of London introduced chemical cardiac arrest by injecting high-dose potassium citrate (\,solution) into the aortic root.
Pitfall: Abandoned by the early 1960s after worldwide reports revealed extensive myocardial necrosis, intracellular calcium overload, and postoperative heart failure due to hyperosmolar citrate toxicity.
Modern Crystalloid Cardioplegia (1970s):
David Hearse, Mark Braimbridge, and colleagues developed the extracellular St. Thomas' Hospital Solution No. 1 and No. 2, utilizing balanced potassium chloride () coupled with magnesium and procaine to induce safe electromechanical diastolic arrest.
H. J. Bretschneider (1975) introduced intracellular, low-sodium, histidine-tryptophan-ketoglutarate (HTK) solution for combined organ preservation and cardiac surgery.
Cold Blood Cardioplegia (1970s–1980s):
Gerald D. Buckberg at UCLA systematically refined blood-derived cardioplegic regimens, demonstrating that mixing cold blood with crystalloid arrest agents (e.g., ratio) provided oncotic support, buffer capacity, free-radical scavengers, and intermittent reoxygenation.
del Nido Solution (1990s):
Developed by Pedro del Nido and colleagues at Boston Children's Hospital for pediatric myocardial preservation, integrating lidocaine (a sodium channel blocker) alongside potassium to minimize calcium influx, subsequently widely adopted in adult cardiac surgery for single-dose administration.
6. Ancillary Circuit Innovations
Biocompatible Tubing & Cannulas: Replacement of red rubber tubing with non-pyrogenic polyvinyl chloride (PVC) by DeWall and Lillehei (1955); development of flexible wire-reinforced venous cannulas and thin-walled aortic cannulas to maximize internal diameter while reducing velocity shear stresses.
Cardiotomy Suction and Autotransfusion: Denton Cooley and D. C. Bloodwell formalized continuous coronary suction techniques in the early 1960s; Gerald Klebanoff developed the prototype automated cell salvage system (Cell Saver) in 1974 to wash, hemoconcentrate, and reinfuse shed mediastinal red blood cells.
Arterial Line Filtration: Introduction of Dacron wool depth filters by Roy Swank (1961), which subsequently transitioned in the 1970s to microporous woven polyester screen filters () equipped with air purge lines to intercept microemboli, gas, and platelet-leukocyte aggregates before systemic delivery.